Skip to main content
Clinical Trials/NCT06818721
NCT06818721Not yet recruitingPhase 2

Intravitreal Topotecan for the Prevention or Treatment of Proliferative Vitreoretinopathy in Patients with Rhegmatogenous Retinal Detachment: a Prospective Matched Cohort Study

Unity Health Toronto2 sites in 1 country394 target enrollmentStarted: March 2025Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
394
Locations
2
Primary Endpoint
Rate of recurrent rhegmatogenous retinal detachment secondary to proliferative vitreoretinopathy

Study Overview

Brief Summary

Intravitreal topotecan exhibits strong anti-inflammatory, anti-proliferative, and anti-fibrotic properties, making it a promising option for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Preclinical studies have demonstrated its efficacy in proliferative vitreoretinopathy models, where no adverse events have been reported for doses of 5 µg to 30 µg. This prospective, matched cohort study aims to assess the therapeutic efficacy and safety of intravitreal topotecan for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment patients.

Detailed Description

Patients who provide informed consent for participation in the experimental study arm will undergo standard-of-care retinal detachment surgery with intravitreal topotecan (8 µg/0.05 mL), diluted in sterile saline and administered preoperatively within one week before surgery, as well as one week postoperatively. Matched historical control patients who received standard-of-care retinal detachment surgery without intravitreal topotecan will be eligible for study participation. Both the experimental and historical control study arms will be further divided into two groups: (i) patients with rhegmatogenous retinal detachment who exhibit high-risk characteristics of proliferative vitreoretinopathy on optical coherence tomography or have early proliferative vitreoretinopathy confirmed by clinical examination, and (ii) patients with rhegmatogenous retinal detachment who have neither high-risk characteristics of proliferative vitreoretinopathy nor a history of proliferative vitreoretinopathy.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients aged 18 years and older
  • Patients who undergo pneumatic retinopexy, pars plana vitrectomy and/or scleral buckling for rhegmatogenous retinal detachment
  • Patients who are voluntarily able and willing to participate
  • Patients undergoing combined phacoemulsification and pars plana vitrectomy and/or scleral buckling will also be included. Any surgical technique will be considered, including relaxing retinotomy or retinectomy during pars plana vitrectomy.

Exclusion Criteria

  • Patients with a history of exudative retinal detachment
  • Patients with severe non-proliferative or proliferative diabetic retinopathy
  • Patients with other planned ocular surgery following pars plana vitrectomy
  • Female patients of childbearing age (i.e. less than 50 years old) who intend to become pregnant over the course of the study
  • Patients with pre-existing bone marrow suppression or cytopenias
  • Patients with pre-existing interstitial lung disease

Arms & Interventions

Intravitreal topotecan with retinal detachment surgery

Experimental

Intravitreal topotecan 8 µg/0.05mL, diluted in sterile saline and administered preoperatively, within one week prior to surgery, as well as one week postoperatively.

Intervention: Intravitreal topotecan (Drug)

Intravitreal topotecan with retinal detachment surgery

Experimental

Intravitreal topotecan 8 µg/0.05mL, diluted in sterile saline and administered preoperatively, within one week prior to surgery, as well as one week postoperatively.

Intervention: Retinal detachment surgery (Procedure)

Retinal detachment surgery

Active Comparator

Historical control patients who previously received standard of care surgery for rhegmatogenous retinal detachment without intravitreal topotecan.

Intervention: Retinal detachment surgery (Procedure)

Outcomes

Primary Outcomes

Rate of recurrent rhegmatogenous retinal detachment secondary to proliferative vitreoretinopathy

Time Frame: 6 months or last follow-up

Secondary Outcomes

  • Grade of proliferative vitreoretinopathy(6 months or last follow-up)
  • Rate of primary retinal reattachment(6 months or last follow-up)
  • Rate of final retinal reattachment(6 months or last follow-up)
  • Best-corrected visual acuity(6 months or last follow-up)
  • Change in best-corrected visual acuity from baseline(6 months or last follow-up)
  • Rate of complications(6 months or last follow-up)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Intravitreal Topotecan for Prevention or... | Clinical Trial